142 related articles for article (PubMed ID: 23610115)
1. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
2. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
3. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Hegde U; Patel V; Kaloudis E
Int J Urol; 2013 Jun; 20(6):644-5. PubMed ID: 23186003
[No Abstract] [Full Text] [Related]
4. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
5. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
[TBL] [Abstract][Full Text] [Related]
6. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
7. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
8. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Kumar S
J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
[No Abstract] [Full Text] [Related]
9. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
10. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitor induced pancreatitis.
Sevin A; Chen A; Atkinson B
J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
[TBL] [Abstract][Full Text] [Related]
12. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Wolter P; Beuselinck B; Pans S; Schöffski P
Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
[No Abstract] [Full Text] [Related]
13. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Dasanu CA; Alexandrescu DT; Dutcher J
South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
[TBL] [Abstract][Full Text] [Related]
14. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
Stieb S; Riesterer O; Brüssow C; Pestalozzi B; Guckenberger M; Weiler S
Strahlenther Onkol; 2016 May; 192(5):342-8. PubMed ID: 26907093
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic atrophy--a new late toxic effect of sorafenib.
Hescot S; Vignaux O; Goldwasser F
N Engl J Med; 2013 Oct; 369(15):1475-6. PubMed ID: 24106956
[No Abstract] [Full Text] [Related]
16. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Konca Degertekin C; Coşkun U; Baloş Törüner F; Aktürk M; Demirci U
Endocrine; 2012 Dec; 42(3):756-7. PubMed ID: 22562706
[No Abstract] [Full Text] [Related]
17. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
[TBL] [Abstract][Full Text] [Related]
18. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
Rexer H;
Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
[No Abstract] [Full Text] [Related]
19. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
20. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Fairfax BP; Pratap S; Roberts IS; Collier J; Kaplan R; Meade AM; Ritchie AW; Eisen T; Macaulay VM; Protheroe A
BMC Cancer; 2012 Dec; 12():590. PubMed ID: 23231599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
